BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $4151.T readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07623616-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~ziftomenib readout (P2) · Kyowa Kirin Co.\, Ltd. $4151.T
DESCRIPTION:A Phase 2 Clinical Study of Ziftomenib in Patients With Relapse
 d or Refractory NPM1-Mutated Acute Myeloid Leukemia\n\nPrimary completion 
 date: 2027-03 (estimated) — month only\, shown on the 1st\nPhase 2 · On
 cology · Acute Myeloid Leukemia (AML)\nEnrollment: 6 · Sites: 20\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT07623616\nhttps://clinicaltrials.gov/study/NCT07623616
URL:https://datacutoff.com/radar.html?nct=NCT07623616
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
